大豆イソフラボン・エクオール

Sourcing reality varies sharply by ingredient form. Standardised aglycone-form soy isoflavone powders (e.g., koji-fermented preparations) are typically available in 1–10 kg trial lots and 50–500 kg commercial lots with 4–10 week lead times. Fermented S-equol concentrate is a much narrower market: Otsuka's EQUELLE® is the dominant commercial source in Japan and is sold as a finished consumer product, not as a bulk ingredient. Brands seeking S-equol as a bulk ingredient must work with the limited set of S-equol producers globally and should expect long lead times and IP-related restrictions on positioning.

Standard documentation includes: (1) per-lot CoA reporting individual isoflavone composition (daidzein, genistein, glycitein and their glycoside forms) by HPLC, total isoflavone content as aglycone-equivalent, residual solvents, heavy metals, microbiology, and allergen status (soy is a Codex-recognised major allergen and must be declared); (2) GMO status declaration — Identity-Preserved (IP) non-GMO soy is the norm for premium positioning, with supporting traceability paperwork; (3) for fermented preparations, the fermentation organism declaration and a process flow sufficient to confirm the absence of live bacteria in the finished material; (4) for S-equol products, a chiral purity statement (S- vs R-/racemic) since only S-equol is the biologically active form produced by gut bacteria.

Identity-Preserved (IP) non-GMO soy is the standard input for export-oriented Japanese soy isoflavone production; many Japanese suppliers source IP non-GMO soybeans from certified North American or domestic supply chains. Kosher and halal certifications are commonly available because the production process is plant-based with no animal-derived inputs, but should be confirmed per supplier and per ingredient grade. Organic-certified soy isoflavone powders exist but are rarer and command a premium — verify the certifying body (JAS / EU / USDA NOP) and confirm whether the certification covers the soy alone or the full extraction process.

Three areas warrant explicit contract treatment: (1) IP and trademark scope — EQUELLE®, Equelle®, ゆらぎ期®, Fuji-Flavone, AglyMax and similar marks are registered to specific companies and cannot be used by buyers without licensing; spell out in the supply agreement whether the supplier permits any reference to the upstream brand; (2) regulatory positioning — fix in writing which market(s) the buyer intends to sell into and confirm the supplier's documentation is sufficient for that market (EU Novel Food considerations, US DSHEA structure-function claim limits, China NMPA health-food filing, Korea MFDS health-functional-food review); (3) for FFC-eligible positioning in Japan, clarify whether the supplier provides systematic-review-ready clinical data or whether the buyer must build its own dossier.

Per-kilo pricing is driven primarily by (1) form — direct fermented S-equol carries a multiple-order-of-magnitude premium over standardised soy isoflavone aglycone powder, which in turn carries a premium over crude soy extract; (2) standardisation — guaranteed minimum aglycone-equivalent content (e.g., 40% vs 10%) significantly affects unit price; (3) IP status — patented or branded ingredients (e.g., AglyMax®) may carry licensing components in the price; (4) raw-soy commodity pricing and IP non-GMO supply availability. Fluctuations in the global non-GMO soy market and any disruption in Japanese fermentation capacity can both move prices.